Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 BioSpaceEli Lilly's shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter.Metabolic & GLP-1Read full story pharminent August 5, 2026 (Last updated: August 8, 2026) BioSpace Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. Metabolic & GLP-1 Read full story Post navigation Previous: AsymBio to secure $184m to support growth in biologics manufacturingNext: Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026